Synthesis and evaluation of the hypoglycemic and hypolipidemic activity of novel 5-benzylidene-2,4-thiazolidinedione analogs in a type-2 diabetes model

Medicinal Chemistry Research

Volumn 20, Issue 5, 2011, Pages 642-647

  Mehendale Munj, Sonali ^a   Ghosh, Rumi ^a   Ramaa, C S ^a  

^a BHARATI VIDYAPEETH S COLLEGE OF PHARMACY   (India)

Author keywords

5 Benzylidene 2,4 thiazolidinedione; Hypoglycemic activity; Knoevenagel condensation; Streptozotocin; Type 2 diabetes

Indexed keywords

2 [4 [(2,4 DIOXOTHIAZOLIDIN 5 YLIDENE)METHYL]PHENOXY] N (5 NITROTHIAZOL 2 YL)ACETAMIDE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; 5 [2 [4 [(2,4 DIOXOTHIAZOLIDIN 5 YLIDENE)METHYL]PHENOXY]ACETYL] 2 HYDROXYBENZAMIDE; CHOLESTEROL; GLUCOSE; PIOGLITAZONE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHEMICAL REACTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; GLUCOSE BLOOD LEVEL; LIPID DIET; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RAT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 80052030218     PISSN: 10542523     EISSN: 15548120     Source Type: Journal    
DOI: 10.1007/s00044-010-9359-5     Document Type: Article

References (18)

1. Bedir A, Aliyazicioglu Y, Kahraman H, Yurdakul Z, Uysal M, Suvaci DE, Okuyucu A, Kelek MH, Alvur M (2006) Genotoxicity in rats treated with the antidiabetic agent, rosiglitazone. Environ Mol Mutagen 47:718-724 (Pubitemid 44917684)
2. FDA (2007) Safety alerts for drugs, biologics, medical devices and dietary supplements. http://www.fda.gov/medwatch/safety/2007/safety07.htm#rosi- pio. Accessed 20 September 2008
3. Forman LM, Simmons DA, Diamond RH (2000) Hepatic failure in a patient taking rosiglitazone. Ann Intern Med 132:118-121 (Pubitemid 30044178)
4. Kenned FP (2003) Do thiazolidinediones cause congestive heart failure? Mayo Clin Proc 78:1076-1077
5. Lohray VB, Lohray BB (2007) Drug discovery and development, volume 2: drug development. Wiley-Interscience, p 91
6. Lohray BB, Bhushan V, Rao BP, Madhavan GR, Murali N, Rao KN, Reddy AK, Rajesh BM, Reddy PG, Chakrabarti R, Vikramadithyan RK, Rajagopalan R, Rao NVSM, Jajoo HK, Subramaniam S (1998) Novel euglycemic and hypolipidemic agents. 1. J Med Chem 41:1619-1630
7. Lohray BB, Bhushan V, Reddy AS, Rao PB, Reddy NJ, Harikishore P, Haritha N, Vikramadityan RK, Chakrabarti R, Rajagopalan R, Katnen K (1999) Novel euglycemic and hypolipidemic agents. 4. Pyridyl- and quinolinyl-containing thiazolidinediones. J Med Chem 42:2569-2581 (Pubitemid 29344297)
8. Lohray BB, Lohray VB, Bajji AC, Kalchar S, Poondra RR, Padakanti S, Chakrabarti R, Vikramadithyan RK, Misra P, Julur S, Rao NVS, Rajagopalan R (2001) (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy] phenyl]-2-ethoxypropanoic Acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity. J Med Chem 44:2675-2678 (Pubitemid 32852157)
9. Memose K, Hatanaka C, Satoru O, Sohda T (1991) Studies on Antidiabetic agents. X. Synthesis and biological activities of pioglitazone and related compounds. Chem Pharm Bull 39:1440-1445
10. Reddy AK, Lohray BB, Bhushan V, Bajji AC, Reddy KV, Reddy PR, Krishna HT, Rao NI, Jajoo HK, Rao NVSM, Chakrabarti R, Dileepkumar T, Rajagopalan R (1999) Novel antidiabetic and hypolipidemic agents. 3. Benzofuran-containing thiazolidinediones. J Med Chem 42:1927-1940 (Pubitemid 29269626)
11. Sauerberg P, Pettersson I, Jeppesen L, Bury PS, Mogensen JP, Wassermann K, Brand CL, Sturis J, Fleckner J, Andersen AT, Mortensen SB, Svensson LA, Rasmussen HB, Lehmann SV, Polivka Z, Sindelar K, Panajotova V, Ynddal L, Wulff EM (2002) Novel tricyclic-r-alkyloxyphenylpropionic acids: dual PPARa/c agonists with hypolipidemic and antidiabetic activity. J Med Chem 45:789-804 (Pubitemid 34173932)
12. Scheen AJ (2001) Thiazolidinediones and liver toxicity. Diabetes Metab 27:305
13. Sengpracha W (2005) Synthesis of biologically active indole-fused heterocyclic derivatives. University of Wollongong, Australia
14. Shrinivasan K, Viswanand B, Asrat L, Kaul CL, Ramarao P (2005) Combination of high-fat diet-fed and low dose of streptozotocintreated rat: a model for type 2 diabetes and pharmacological screening. Pharmacol Res 52:313-320 (Pubitemid 41175991)
15. Skyler JS (2004) Diabetes mellitus: pathogenesis and treatment strategies. J Med Chem 47:4113-4117 (Pubitemid 39045414)
16. Sohda T, Mizuno K, Tawada H, Sugiyama Y, Fugita T, Kawamatsu Y (1982) Studies on antidiabetic agents. I. Synthesis of 5-[4-92- methyl-2-phenylpropoxy) -benzyl]thiazolidine-2,4-dione (AL- 321) and related compounds. Chem Pharm Bull 30:3563-3573 (Pubitemid 13210096)
17. Tanis SP, Parker TT, Colca JR, Fisher RM, Kletzein RF (1996) Synthesis and biological activity of metabolites of the antidiabetic, antihyperglycemic agent pioglitazone. J Med Chem 39:5053-5063 (Pubitemid 27008952)
18. Williams DA, Lemke TL (2005) Foye's principles of medicinal chemistry. B.I. Publication Pvt. Ltd, New Delhi, p 645